Clincosm LogoSign in Get a demo

Reminder Messages for Lung Cancer Screening

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05952778
Collaborator
(none)
130
Enrollment
1
Location
30.4
Anticipated Duration (Months)
4.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To test lung cancer screening reminder messages to help adults who 1) 50 to 80 years of age, 2) smoke or have smoked, and 3) do not have history of lung cancer by self-report.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Primary Objectives:

    -In this project we will develop, refine, and test reminders for LCS to ensure they are acceptable to patients who have a history of cigarette use.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    130 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Reminder Messages for Lung Cancer Screening
    Actual Study Start Date :
    Jun 20, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Ottawa Acceptability questionnaires [through study completion; an average of 1 year]

      Score scale ranges Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Adults ages 50-80 years

    • Currently use cigarettes or have smoked in the past

    • English or Spanish speaker (based on self-report)

    Exclusion Criteria:

    • History of lung cancer (based on self-report)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 M D Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center

    Investigators

    • Principal Investigator: Robert Volk, MD, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT05952778
    Other Study ID Numbers:
    • 2023-0378
    • NCI-2023-05185
    First Posted:
    Jul 19, 2023
    Last Update Posted:
    Jul 27, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Lung Neoplasms

    Study Results

    No Results Posted as of Jul 27, 2023